Pfizer said the CRL relates to matters noted in the February warning letter. John Young, president of the Essential Health, unit Tuesday told analysts Pfizer has provided the FDA with its corrective and preventative action plan for McPherson, and has been "diligently working to address the items outlined in the warning letter." But the manufacturing problems at the McPherson fill-finish plant have bled beyond Pfizer, derailing the expected approval earlier this year of a generic of Teva's long-acting Copaxone being developed by Sandoz unit and Cambridge, Massachusetts-based Momenta.